Stay updated on Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4, signaling a new version of the page. This indicates a maintenance update without altering the study information.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedThe study record includes metadata updates: a new last update date, revised estimated study completion dates, and removal of the old registry identifier, with other historical dates added. These changes update timeline and registry references but do not modify treatment, eligibility, or participating locations.SummaryDifference0.4%

- Check33 days agoChange DetectedPage revision updated from v3.6.2 to v3.6.3, indicating a minor platform update. This change does not affect study content, eligibility, or outcomes.SummaryDifference0.1%

- Check40 days agoChange DetectedThe page now displays Revision: v3.6.2, replacing the previous v3.6.0. This signals a minor update to the page version rather than a change to the study content.SummaryDifference0.1%

- Check55 days agoChange DetectedRecruitment status is updated to indicate enrollment is closed, with the addition of guidance sections for reading the study record and joining a study; the page also shows an updated Intervention/Treatment header and a new revision note (Revision: v3.6.0).SummaryDifference0.4%

- Check62 days agoChange DetectedThe page revision updated from v3.5.4 to v3.5.5, indicating a small patch or update to the page's software or rendering. The overall content and purpose of the study page appear unchanged.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.